Cutting edge research for novel therapies of heart and lung diseases

References
1 Keeley EC, Mehrad B, Strieter RM. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. Thromb Haemost 2009; 101: 613-618.
2 Hecquet CM, Malik AB. Role of H202-activated TRPM2 calcium channel in oxidant-induced endothelial injury. Thromb Haemost 2009; 101: 619-625.
3 Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost 2009; 101: 626-634.
4 Garcia-Dorado D, Agulló L, Sartorio CL, RuizMeana M. Myocardial protection against reperfusion injury: The cGMP pathway. Thromb Haemost 2009; 101: 635-642.
5 Dragun D, Philippe A, Catar R, Hegner B. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost 2009; 101: 643-648.
6 van Buul JD, Hordijk PL. Endothelial adapter proteins in leukocyte transmigration. Thromb Haemost 2009; 101: 649-655.
7 Eddy AA. Fibrinolytic serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 2009; 101: 656-664.
8 Wygrecka M, Jablonska E, Guenther A, Preissner KT, Markart P. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008; 99: 494-501.
9 Ruppert C, Markart P, Schmidt R, Grimminger F, Seeger W, Lehr CM, Günther A. Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. Thromb Haemost 2003; 89: 53-64.